预约演示
Chemomab touts study confirming CCL24 link to systemic sclerosis severity
2024-04-18
临床2期免疫疗法上市批准临床结果
In addition to thickening and hardening of the skin, systemic sclerosis can cause joint pain and problems to the internal organs. Credit: Numstocker via Shutterstock.
Clinical-stage biotech Chemomab Therapeutics has annosystemic sclerosision of a stjoint painghting that high serum CCL24 levels are linked to more severe forms of systemic sclerosis (SSc).
SSc is a chronic autoimChemomab Therapeuticsrised by excessive collagen production, leading to thickening and hardeCCL24of the skin and various internal organs. Afsystemic sclerosis (SSc)vessels, muscles, and internal organs, the condition causes symptoms like joint pain, skin tightening, and organ dysfunction.
The studychronic autoimmune diseaseis Care and Research journal and conducted at the University of Leeds in the UK, looked at 200 patients with SSc. It found that a quarter of them had high levels of CCL24 in their blood, even though they were receiving standarjoint paint. Higher CCL24 levels were linked to more severe forms of the condition, including worse skin problems and lung issues.
Scientists identified that high CCL24 levels were predictive of lung problems worseniUniversity of Leedsatients with higher levels of the protein had a higher risk of dying from SSc within 10 years, wCCL24they said validated CCL24 as an important biomarker.CCL24
Chemomab is developing its own mCCL24onal antibody, CM-101, that neutralises CCL24. Standard treatments for SSc usually involve steroids, immunosuppressants known as conventional disease-modifying anti-rheumatic drugs (DMARDsCCL24 biologic treatments. Genentech’s subcutaneous injection Actemra (tocilizumab) was the first biologic to receive FDA approval in March 2021 to treat the condition.
MediPal gets grant for temperature monitoring and quality certification system for delivered articles
MediPalis currently in a Phase II trial (NCT04595825) for primary sclerosing cholangitis (PSC), with data expected later on in 2024. In February 2023, Chemomab received clearance from the US Food and Drug Administration (FDA) to initiate the Phase II ABATE trial (NCT06210945) of CM-101. The company plans to start enrolment on that study following topline results from the PSC trial, Chemomab’s CEO Adi Mor said in the 18 April release announcing the study.
“These results also reinforce our belief, based on multiple preclinical and patient sample studies, that our novel CCL24-neutralizing antibody CM-101 has substantial potential as a treatment for SSc,” adds Mor.
CM-101 was being investigated in a clinical trial for non-primary sclerosing cholangitis (PSC)wever Chemomab announced in June 2023 that it was parkingChemomabal and putting its resources intFood and Drug Administration (FDA)esults.CM-101Chemomab
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。